MediWound Statistics
Total Valuation
MediWound has a market cap or net worth of $226.68 million. The enterprise value is $175.86 million.
Important Dates
The last earnings date was Thursday, November 20, 2025, before market open.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediWound has 12.82 million shares outstanding. The number of shares has increased by 13.59% in one year.
| Current Share Class | 12.82M |
| Shares Outstanding | 12.82M |
| Shares Change (YoY) | +13.59% |
| Shares Change (QoQ) | +1.73% |
| Owned by Insiders (%) | 1.47% |
| Owned by Institutions (%) | 52.18% |
| Float | 9.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.18 |
| Forward PS | 7.73 |
| PB Ratio | 4.52 |
| P/TBV Ratio | 4.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.65 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.83% and return on invested capital (ROIC) is -29.72%.
| Return on Equity (ROE) | -48.83% |
| Return on Assets (ROA) | -17.42% |
| Return on Invested Capital (ROIC) | -29.72% |
| Return on Capital Employed (ROCE) | -34.57% |
| Revenue Per Employee | $188,577 |
| Profits Per Employee | -$185,622 |
| Employee Count | 111 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 4.59 |
Taxes
In the past 12 months, MediWound has paid $114,000 in taxes.
| Income Tax | 114,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.94% in the last 52 weeks. The beta is 0.07, so MediWound's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -1.94% |
| 50-Day Moving Average | 18.09 |
| 200-Day Moving Average | 18.30 |
| Relative Strength Index (RSI) | 47.42 |
| Average Volume (20 Days) | 79,150 |
Short Selling Information
| Short Interest | 988,573 |
| Short Previous Month | 1.01M |
| Short % of Shares Out | 8.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 18.73 |
Income Statement
In the last 12 months, MediWound had revenue of $20.93 million and -$20.60 million in losses. Loss per share was -$1.90.
| Revenue | 20.93M |
| Gross Profit | 3.88M |
| Operating Income | -23.57M |
| Pretax Income | -20.49M |
| Net Income | -20.60M |
| EBITDA | -22.66M |
| EBIT | -23.57M |
| Loss Per Share | -$1.90 |
Full Income StatementBalance Sheet
The company has $59.09 million in cash and $8.27 million in debt, giving a net cash position of $50.82 million or $3.96 per share.
| Cash & Cash Equivalents | 59.09M |
| Total Debt | 8.27M |
| Net Cash | 50.82M |
| Net Cash Per Share | $3.96 |
| Equity (Book Value) | 50.16M |
| Book Value Per Share | 3.91 |
| Working Capital | 43.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.74 million and capital expenditures -$3.86 million, giving a free cash flow of -$18.60 million.
| Operating Cash Flow | -14.74M |
| Capital Expenditures | -3.86M |
| Free Cash Flow | -18.60M |
| FCF Per Share | -$1.45 |
Full Cash Flow StatementMargins
Gross margin is 18.53%, with operating and profit margins of -112.59% and -98.43%.
| Gross Margin | 18.53% |
| Operating Margin | -112.59% |
| Pretax Margin | -97.89% |
| Profit Margin | -98.43% |
| EBITDA Margin | -108.27% |
| EBIT Margin | -112.59% |
| FCF Margin | n/a |
Dividends & Yields
MediWound does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.59% |
| Shareholder Yield | -13.59% |
| Earnings Yield | -9.09% |
| FCF Yield | -8.21% |
Analyst Forecast
The average price target for MediWound is $37.50, which is 112.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.50 |
| Price Target Difference | 112.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 45.45% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 20, 2022. It was a reverse split with a ratio of 1:7.
| Last Split Date | Dec 20, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |